ESSA Pharma (EPIX) News Today $1.40 -3.80 (-73.08%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Essa Pharma terminates Phase 2 study of masofaniten combo in mCRPCNovember 2 at 3:48 AM | markets.businessinsider.comEssa Pharma downgraded to Hold from Buy at JonesResearchNovember 1 at 10:47 PM | markets.businessinsider.comEssa Pharma downgraded to Hold from Buy at JefferiesNovember 1 at 10:47 PM | markets.businessinsider.comEssa Pharma Shares Drop After Lead Drug Candidate FailsNovember 1 at 5:47 PM | marketwatch.comCancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination TherapyNovember 1 at 5:47 PM | benzinga.comESSA Pharma tanks after terminating trial for its prostate cancer treatmentNovember 1 at 5:47 PM | msn.comESSA Pharma (NASDAQ:EPIX) Share Price Crosses Below Fifty Day Moving Average - Should You Sell?ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below Fifty Day Moving Average - What's Next?November 1 at 4:39 AM | marketbeat.comESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerOctober 31 at 8:57 PM | prnewswire.comESSA Pharma (NASDAQ:EPIX) Share Price Crosses Below 50-Day Moving Average - Here's What HappenedOctober 24, 2024 | americanbankingnews.comESSA Pharma (NASDAQ:EPIX) Stock Passes Above Fifty Day Moving Average - What's Next?ESSA Pharma (NASDAQ:EPIX) Share Price Passes Above Fifty Day Moving Average - Here's What HappenedOctober 16, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Stock Price Passes Above 50-Day Moving Average of $5.52ESSA Pharma (NASDAQ:EPIX) Stock Passes Above 50-Day Moving Average of $5.52September 27, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Above 50-Day Moving Average of $5.44ESSA Pharma (NASDAQ:EPIX) Shares Pass Above Fifty Day Moving Average of $5.44September 19, 2024 | marketbeat.comESSA Pharma shares poised for growth as PSA90 rates improve in mCRPC trialSeptember 18, 2024 | uk.investing.comESSA Pharma maintains Overweight rating from Piper SandlerSeptember 18, 2024 | uk.investing.comESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth PlansSeptember 17, 2024 | finance.yahoo.comBuy Rating Affirmed for ESSA Pharma on Strong Clinical Data and Promising Future ProspectsSeptember 15, 2024 | markets.businessinsider.comESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressSeptember 13, 2024 | prnewswire.comESSA Pharma to Present at the 2024 Cantor Global Healthcare ConferenceSeptember 11, 2024 | prnewswire.comESSA Pharma Inc. (NASDAQ:EPIX) COO Peter Virsik Sells 2,082 SharesSeptember 4, 2024 | insidertrades.comPiper Sandler Remains a Buy on ESSA Pharma (EPIX)August 30, 2024 | markets.businessinsider.comESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $5.04ESSA Pharma (NASDAQ:EPIX) Shares Pass Below 50-Day Moving Average of $5.04August 22, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Share Price Passes Below 50 Day Moving Average of $5.09ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $5.09August 14, 2024 | marketbeat.comEPIX: Updated Masofaniten plus Enzalutamide Dose Escalation Data to be Presented at ESMO 2024…August 8, 2024 | msn.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024August 5, 2024 | prnewswire.comESSA Pharma to Present at the JonesHealthcare Seaside SummitJuly 8, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Shares Cross Below 50 Day Moving Average of $5.83ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below 50-Day Moving Average of $5.83July 4, 2024 | marketbeat.comESSA Pharma Inc. (NASDAQ:EPIX) Sees Large Decline in Short InterestESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 843,700 shares, a decline of 7.6% from the May 15th total of 913,100 shares. Based on an average daily trading volume, of 58,700 shares, the days-to-cover ratio is currently 14.4 days.June 19, 2024 | marketbeat.com2,298,662 Shares in ESSA Pharma Inc. (NASDAQ:EPIX) Purchased by RTW Investments LPRTW Investments LP purchased a new position in ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) (TSE:EPI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,298,662 shares of the company'June 7, 2024 | marketbeat.comESSA Pharma to Present at the Jefferies Global Healthcare ConferenceMay 30, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Share Price Passes Below Fifty Day Moving Average of $7.33ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Below 50 Day Moving Average of $7.33May 24, 2024 | marketbeat.comInsider Stock Buying Reaches US$709.0k On ESSA PharmaMay 21, 2024 | finance.yahoo.comOppenheimer Reiterates "Outperform" Rating for ESSA Pharma (NASDAQ:EPIX)Oppenheimer reissued an "outperform" rating and set a $17.00 target price on shares of ESSA Pharma in a report on Thursday.May 16, 2024 | marketbeat.comBuy Rating Endorsed for ESSA Pharma on Robust Pipeline and Market Expansion PotentialMay 14, 2024 | markets.businessinsider.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024May 14, 2024 | prnewswire.comShort Interest in ESSA Pharma Inc. (NASDAQ:EPIX) Drops By 13.5%ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 802,800 shares, a drop of 13.5% from the March 15th total of 928,600 shares. Based on an average trading volume of 154,100 shares, the days-to-cover ratio is presently 5.2 days.April 14, 2024 | marketbeat.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | finance.yahoo.comESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 9, 2024 | prnewswire.comESSA Pharma (NASDAQ:EPIX) Is In A Strong Position To Grow Its BusinessApril 8, 2024 | finance.yahoo.comEssa Pharma COO sells shares worth over $5,500April 7, 2024 | investing.comESSA Pharma Inc EPIXApril 5, 2024 | morningstar.comESSA Pharma Inc. (NASDAQ:EPIX) Short Interest UpdateESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the recipient of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 979,400 shares, a decline of 13.3% from the February 14th total of 1,130,000 shares. Based on an average daily volume of 154,800 shares, the days-to-cover ratio is presently 6.3 days. Approximately 4.8% of the shares of the stock are sold short.March 16, 2024 | marketbeat.comEPIX Jul 2024 7.500 callMarch 10, 2024 | finance.yahoo.comEPIX Jul 2024 12.500 putMarch 10, 2024 | finance.yahoo.comESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSMarch 7, 2024 | prnewswire.comShort Interest in ESSA Pharma Inc. (NASDAQ:EPIX) Grows By 5.2%ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) (TSE:EPI) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 1,410,000 shares, an increase of 5.2% from the January 15th total of 1,340,000 shares. Based on an average daily trading volume, of 148,200 shares, the short-interest ratio is currently 9.5 days. Approximately 7.1% of the shares of the company are sold short.February 16, 2024 | marketbeat.comESSA Pharma (NASDAQ:EPIX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPSESSA Pharma (NASDAQ:EPIX - Get Free Report) (TSE:EPI) issued its quarterly earnings results on Tuesday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03.February 14, 2024 | marketbeat.comESSA Pharma: Q1 Earnings InsightsFebruary 13, 2024 | benzinga.comESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023February 13, 2024 | finance.yahoo.comESSA Pharma Inc. (NASDAQ:EPIX) Shares Sold by Rhenman & Partners Asset Management ABRhenman & Partners Asset Management AB decreased its holdings in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) (TSE:EPI) by 34.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 234,000 shares ofFebruary 12, 2024 | marketbeat.comESSA Pharma Inc Executive Peter Virsik Sells 72,782 SharesFebruary 8, 2024 | finance.yahoo.com Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here EPIX Media Mentions By Week EPIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EPIX News Sentiment▼-0.340.43▲Average Medical News Sentiment EPIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EPIX Articles This Week▼81▲EPIX Articles Average Week Get ESSA Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mesoblast News Arcutis Biotherapeutics News Applied Therapeutics News CARGO Therapeutics News Phibro Animal Health News Phathom Pharmaceuticals News Cullinan Therapeutics News Zymeworks News Rapport Therapeutics News AnaptysBio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EPIX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
